In agreement, Taketani et al. showed that all FP agonists that are currently used as glaucoma treatments, including latanoprost, inhibited adipogenesis by stimulating the FP receptor in 3T3-L1 cells.21 In addition, FP agonists limited the induction of Pparg, Cebpa, and Cebpb during adipocyte differentiation (Figs. 6 and 7). This evidence concerns the gene CEBPB and glaucoma.